Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Sponsor: Translational Research in Oncology
A PHASE2 clinical study on Ovarian Neoplasms, this trial is completed. The trial is conducted by Translational Research in Oncology and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Translational Research in Oncology
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States , Aurora, United States , Bakersfield, United States , Berlin, Germany , Calgary, Canada , Chicago, United States , Cork, Ireland , Dublin, Ireland , Erlangen, Germany , Fullerton, United States and 21 more locations